A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 410,000 shares of BMY stock, worth $21.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
410,000
Previous 461,514 11.16%
Holding current value
$21.8 Million
Previous $25 Million 31.97%
% of portfolio
0.04%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

SELL
$40.25 - $52.99 $2.07 Million - $2.73 Million
-51,514 Reduced 11.16%
410,000 $17 Million
Q1 2024

Apr 15, 2024

BUY
$47.98 - $54.4 $3.57 Million - $4.05 Million
74,486 Added 19.25%
461,514 $25 Million
Q4 2023

Jan 30, 2024

SELL
$48.48 - $57.85 $3.34 Million - $3.98 Million
-68,850 Reduced 15.1%
387,028 $19.9 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $21 Million - $23.4 Million
362,065 Added 385.94%
455,878 $26.5 Million
Q2 2023

Jul 21, 2023

SELL
$63.71 - $70.74 $136,084 - $151,100
-2,136 Reduced 2.23%
93,813 $6 Million
Q1 2023

Apr 25, 2023

BUY
$65.71 - $74.53 $6.3 Million - $7.15 Million
95,949 New
95,949 $6.65 Million
Q4 2020

Feb 10, 2021

SELL
$57.74 - $65.43 $3.64 Million - $4.13 Million
-63,110 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $3.62 Million - $4.02 Million
63,110 New
63,110 $3.9 Million
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $206,671 - $241,619
-3,770 Closed
0 $0
Q1 2020

May 01, 2020

SELL
$46.4 - $67.43 $1,392 - $2,022
-30 Reduced 0.79%
3,770 $234,000
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $186,998 - $243,922
3,800 New
3,800 $242,000
Q1 2018

Apr 26, 2018

SELL
$59.92 - $68.98 $436,936 - $503,002
-7,292 Closed
0 $0
Q4 2017

Jan 19, 2018

BUY
$59.94 - $65.35 $437,082 - $476,532
7,292
7,292 $458,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wealth Enhancement Advisory Services, LLC Portfolio

Follow Wealth Enhancement Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Enhancement Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Enhancement Advisory Services, LLC with notifications on news.